News
Timing Is Everything: CAR T for Follicular Lymphoma
Experts debated about whether and when patients with relapsed/refractory follicular lymphoma should receive CAR T-cell therapy.
News
ALL: Which Life-Saving Tx Is Best?
Both CAR T-cell therapy and bispecific antibodies are helping patients with patients with R/R ALL live longer, but which treatment is better?
News
Magic Wand Initiative Empowers Dermatologists to Innovate
The program, started to help Massachusetts dermatologists innovate, has mushroomed into a pipeline for innovation across specialties.
News
What’s new in acne treatment?
Many patients and their caregivers are enthusiastic about the idea of treatment that does not involve pharmaceuticals and that these options,...
News
DLBCL treatment options: CAR T outperforms ASCT
Relapsed and refractory DLBCL patients treated with CAR T-cell therapy achieved better outcomes than with autologous stem cell transplants.
News
Rare lymphomas: Desperately seeking new txs
Experts seek global collaboration to develop novel therapies for peripheral T-cell lymphomas, a rare form of non-Hodgkin lymphoma with many...
News
Frontline myeloma treatments: ASCT vs. CAR T
Experts debate whether CAR T-cell therapy could eventually replace autologous stem cell transplant (ASCT) as the standard of care for multiple...
News
Nationwide hematologists shortage: What’s being done?
Efforts are underway to alleviate an acute shortage of U.S. physicians who’ve been trained to treat hemostasis, thrombosis and other blood...
News
CLL combo treatment: Phase-3 study inconclusive
Results of the clinical trial of a CLL drug triplet therapy, presented at ASCO 2023, showed that more data are needed to determine its long-term...
News
New CLL meds: Improved survival rates, 1990-2018
A just-published retrospective study shows nearly 30 years of steady progress in lengthening the lives of U.S. adults with CLL and other leukemias...
News
DLBCL: Major new treatment breakthroughs
After decades of slow progress, new drugs and therapies are paving the way to more effective treatment of DLBCL.
News
Experts debate reducing ASCT for multiple myeloma
Overall survival following multidrug regimens and transplant are on par, raising questions about the best frontline therapy for multiple myeloma...
News
Frontline CLL treatment: Avoiding adverse events
Single-agent frontline therapy helps patients with CLL live longer, but those at high risk of relapse may benefit from multiagent treatment.
News
Relapsed CLL: New approaches prolong survival
Venetoclax, with a second-generation generation Bruton’s tyrosine kinase inhibitor, can lead patients with relapsed CLL back to remission.
News
MRD: Powerful metric for CLL research
New study showed how leukemia specialists can harness measurable residual disease to gauge the efficacy of novel treatment options.